Gilead Sciences, Inc.: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2024–FY2025 (cash from operations less capital spending), from the statements below.
No three-year revenue growth on file: 5% to start with.
US Treasury 10-year yield on Nov 20, 2026: 4.92% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt or cash not on file: 0 to start with.
What today's price assumes
A market value of $193.5 B means free cash flow growing 7.3% a year for 10 years, then 2.5% for ever, at a 9.92% discount rate.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | 0% | 2.5% | 5% | 7.5% | 10% |
|---|---|---|---|---|---|
| 7.92% | -21% | -3% | +17% | +43% | +74% |
| 8.92% | -32% | -18% | -2% | +19% | +44% |
| 9.92% | -41% | -29% | -15% | +2% | +22% |
| 10.92% | -48% | -38% | -26% | -11% | +6% |
| 11.92% | -53% | -44% | -34% | -22% | -7% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of Gilead Sciences, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst its own history
Gilead Sciences, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
18.6×Now below its median of 21.9×, in the bottom quarter of its range; range 13.6× to 958.9× over 28 months.
Price to sales
6.3×Now above its median of 4.9×, in the top quarter of its range; range 3.3× to 6.4× over 30 months.
Price to book
8.5×Now above its median of 7.1×, in the top quarter of its range; range 3.2× to 9.7× over 30 months.
As of Oct 26, 2026
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | — | — | — | — | — | — | Wikidata |
| FY2025to Dec 31, 2025 | $29.4 B | $8.5 B | $10.0 B | $563 M | $9.5 B | $17.4 B | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $28.8 B | $480 M | $10.8 B | $523 M | $10.3 B | $16.7 B | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $27.1 B | $5.7 B | $8.0 B | $585 M | $7.4 B | $18.9 B | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $27.3 B | $4.6 B | $9.1 B | $728 M | $8.3 B | $19.8 B | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $27.3 B | $6.2 B | $11.4 B | $579 M | $10.8 B | $21.4 B | SEC annual report (10-K, 20-F) |